American pharmaceutical company Abbott is going through a challenging period, highlighted by a significant 11.33% decline in the value of its shares during the third quarter of the year.
This decline is largely attributed to persistent problems related to its baby formula and other regulatory complications.
The beginning of the setbacks dates back to the closure of Abbott's main production plant in Michigan, followed by the withdrawal from the market of three types of baby formulas produced in that same Abbott Nutrition factory.
Recently, the FDA issued a warning letter regarding Abbott's Similac Probiotic Tri-Blend product, which led to the suspension of its sales.
The FDA's concern centers on the possibility that this product, classified as an "unapproved drug and unlicensed biological product," could cause serious illnesses or fatal infections in premature babies.
The company faces economic and regulatory challenges, while authorities continue to investigate and analyze reports of adverse events related to its baby products.
The situation reflects a comprehensive crisis that spans stock market and regulatory compliance aspects, generating uncertainty about Abbott's immediate future.
With information from: Salud35.
Receive all industry news in our weekly Newsletter Dialéctica Científica.